Clinical Trial Update: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating CAM-H2, a HER2-directed radioligand, in advanced/metastatic HER2-positive breast, gastric, and gastroesophageal junction cancers wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CAM-H2

Snippet

Sponsor: Precirix | Conditions: Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-06